Difference between revisions of "Cytarabine (Ara-C)"
m (moved Cytarabine (Cytosar) to Cytarabine (Ara-C)) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine ( | + | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine (Ara-C) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabine.pdf Cytarabine (Ara-C) package insert (locally hosted backup)]</ref> |
<br>Route: IV, IT, SC | <br>Route: IV, IT, SC | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/cytarabine.asp Cytarabine ( | + | *[http://chemocare.com/bio/cytarabine.asp Cytarabine (Ara-C) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/cytarabine.asp Cytarabine (Ara-C) patient drug information (Chemocare)]</ref> |
| − | *[http://www.uptodate.com/contents/cytarabine-patient-drug-information Cytarabine ( | + | *[http://www.uptodate.com/contents/cytarabine-patient-drug-information Cytarabine (Ara-C) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cytarabine-patient-drug-information Cytarabine (Ara-C) patient drug information (UpToDate)]</ref> |
| − | |||
| − | |||
| − | |||
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 07:12, 10 December 2011
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IV, IT, SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Cytarabine (Ara-C) patient drug information (Chemocare)[3]
- Cytarabine (Ara-C) patient drug information (UpToDate)[4]